Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA

DESTINY-PanTumor02 late-breaking interim data and DESTINY-CRC02 primary results further support potential of ENHERTU across multiple HER2 expressing cancers



TROPION-Lung02 updated results... | June 11, 2023

Related Keywords

Japan ,United States ,American ,Daiichi Sankyo ,Ken Takeshita ,Datopotamab Deruxtecan ,Daiichi Sankyo Inc ,Sarah Cannon Research Institute ,Astrazeneca ,American Society Of Clinical Oncology Scientific Program ,European Hematology Association Congress ,Clinical Oncology Scientific Program ,Global Head ,Deruxtecan Based Combinations Continuing ,Show Promise ,Oncomine Dx Target ,Presentation Monday ,Newly Diagnosed ,Sarah Cannon Research ,Lung Disease ,Breast Cancer ,Metastatic Gastric Cancer ,Absolute Neutrophil Count ,Fetal Toxicity ,Adverse Reactions ,Positive Metastatic Breast Cancer ,Low Metastatic Breast Cancer ,Reproductive Potential ,Hepatic Impairment ,Prescribing Information ,